Special Report
In January 2025 (U.S. time), the U.S. Food and Drug Administration (FDA) officially approved the Investigational New Drug (IND) application submi...
April 16, 2025 | News
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101&nb...
April 16, 2025 | News
In a courtroom packed with legal heavyweights, global pharmaceutical giant F. Hoffmann-La Roche AG faced off against Indian generic manufac...
April 14, 2025 | Analysis
Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the publication of a new study i...
April 10, 2025 | Report
On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept...
April 09, 2025 | News
Basal Cell Carcinoma CSR Highlights CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients. Optimal Treatment Res...
April 03, 2025 | News
-Ultra-long-acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 36-day half-life in patients with obesity, supp...
April 01, 2025 | News
Hyundai ADM Bio (KOSDAQ symbol 187660) announced on the 24th that its first-in-class pseudo-resistance-targeting agent, PenetriumTM, showed significan...
March 28, 2025 | News
CJ BIO's BiomeNrich™ POST M005 is the first Akkermansia muciniphila-based ingredient to receive New Dietary Ingredient Notification (NDIN) ...
March 28, 2025 | News
Diabetic wounds often lead to severe complications that can result in amputations. These chronic and non-healing wounds are marked by persistent inflammati...
March 27, 2025 | News
Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, announced fina...
March 27, 2025 | News
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...
March 25, 2025 | Report
Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at the 2025 Annual Meeting of the Society ...
March 24, 2025 | Report
Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced ...
March 21, 2025 | News
Most Read
Bio Jobs
News
Editor Picks